Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study
Open Access
- 25 November 2024
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (1) , 471-489
Abstract
Introduction Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in patients with anaemia of chronic kidney disease may lead to increased ESA doses to achieve target haemoglobin levels; however, elevated doses may be associated with increased mortality. Furthermore, patients with hyporesponsiveness to ESAs have poorer clinical outcomes than those who respond well to ESAs. Incidence and clinical characteristics of patients with ESA hyporesponsiveness were explored in a real-world setting. Methods This was a retrospective study of electronic medical records of adults with stage 5 chronic kidney disease receiving renal replacement therapy and ESA treatment, from 1 January 2015 to 31 December 2021. The primary objective was ESA hyporesponsiveness rate/1000 days, with a hyporesponsive event defined as ESA use at an elevated dose, according to National Institute for Health and Care Excellence (NICE) criteria. Other hyporesponsiveness definitions applied were erythropoietin resistance index-defined ESA hyporesponsiveness (ERI) Kidney Disease Improving Global Outcomes (KDIGO) and a clinical practicality algorithm. Results In total, 85,259 patients were included in the analysis; 59.9% were male, median (interquartile range) ESA starting dose was 733.3 (400.0, 1200.0) IU/week and follow-up duration was 2.2 (1.0, 4.2) years. Incidence of ESA hyporesponsiveness varied when applying different definitions; NICE 0.05/1000 days (5.2% of patients), ERI 0.40/1000 days (40.7%), KDIGO 0.15/1000 days (15.4%), and clinical practicality algorithm 0.48/1000 days (47.9%). ESA doses remained higher in hyporesponsive versus responsive patients, yet haemoglobin levels were similar between groups. Conclusion The results from this study, which applied multiple hyporesponsiveness definitions to a large, geographically diverse population of patients with anaemia of CKD, showed variation in ESA hyporesponsiveness incidence rates depending on definitions used and higher ESA doses in hyporesponsive versus responsive patients. These results underscore the need for individualised clinical assessment and thorough evaluation when considering ESA dose adjustments to reach haemoglobin targets. Graphical abstract available for this article. Trial Registration NCT05530291. Graphical AbstractKeywords
Funding Information
- Astellas Pharma Global Development
This publication has 39 references indexed in Scilit:
- Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysisAmerican Journal of Kidney Diseases, 2016
- Anemia of chronic kidney disease: Treat it, but not too aggressivelyCleveland Clinic Journal of Medicine, 2016
- The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measureHemodialysis International, 2016
- Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis PatientsPLOS ONE, 2015
- Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patientsBMC Nephrology, 2015
- Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- The progress of inflammation and oxidative stress in patients with chronic kidney diseaseRenal Failure, 2014
- Tolerability of different oral iron supplements: a systematic reviewCurrent Medical Research and Opinion, 2013
- Conversion from Epoetin Alfa to Darbepoetin Alfa: Effects on Patients’ Hemoglobin and Costs to Canadian Dialysis CentresThe Canadian Journal of Hospital Pharmacy, 2012
- Hepcidin: a molecular link between inflammation and anaemiaNephrology Dialysis Transplantation, 2004